Auris Medical Holding (EARS) Reports Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen
Tweet Send to a Friend
Auris Medical Holding AG (NASDAQ: EARS) today announced that it has completed the recruitment of patients for the Phase 3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
